Mesoblast (MESO) Income from Discontinued Operations (2017 - 2022)
Mesoblast (MESO) posted quarterly Income from Discontinued Operations of 55000.0 for Q3 2022, down 11.29% year-on-year from 62000.0 in Q3 2021, and up 203.77% on a QoQ basis from 53000.0 in Q1 2022.
Mesoblast (MESO) Income from Discontinued Operations (2017 - 2022) Analysis & Trends
Mesoblast (MESO) has reported Income from Discontinued Operations for 6 consecutive years, with 55000.0 the latest figure, recorded in Q3 2022.
- Quarterly Income from Discontinued Operations fell 11.29% year-over-year to 55000.0 in Q3 2022, while the trailing twelve-month figure through Sep 2022 was 512000.0 (up 87.43% YoY) and the FY2021 annual result came in at 819000.0, down 91.3% from the prior year.
- Income from Discontinued Operations climbed to 55000.0 in Q3 2022 per MESO's latest filing, from 53000.0 in the prior quarter.
- Over the last five years, Income from Discontinued Operations for MESO reached as high as 3426000.0 in Q1 2018 and fell as low as 2343000.0 in Q4 2020.
- A 5-year average of 1050055.56 and a median of 875500.0 in 2018 frame the typical range for Income from Discontinued Operations.
- Annual changes were most pronounced in 2019 — Income from Discontinued Operations surged 211.17% — and 2020, when it tumbled 203.26%.
- Year by year, Income from Discontinued Operations stood at 2865000.0 in 2018, then dropped by 20.8% to 2269000.0 in 2019, then slumped by 203.26% to 2343000.0 in 2020, then surged by 75.42% to 576000.0 in 2021, then soared by 109.55% to 55000.0 in 2022.
- According to Business Quant data, Income from Discontinued Operations over the past three periods registered 55000.0, 53000.0, and 576000.0 for Q3 2022, Q1 2022, and Q4 2021 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - | - |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - | - |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn | - |
| 10 | Mesoblast | 18.95 Bn | 18.82 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 55,000.00 |
| Mar 31, 2022 | -53,000.00 |
| Dec 31, 2021 | -576,000.00 |
| Sep 30, 2021 | 62,000.00 |
| Jun 30, 2021 | 65,000.00 |
| Mar 31, 2021 | -1.86 Mn |
| Dec 31, 2020 | -2.34 Mn |
| Sep 30, 2020 | 730,000.00 |
| Jun 30, 2020 | 3.26 Mn |
| Mar 31, 2020 | 1.96 Mn |
| Dec 31, 2019 | 2.27 Mn |
| Sep 30, 2019 | 1.93 Mn |
| Jun 30, 2019 | 3.18 Mn |
| Mar 31, 2019 | 2.21 Mn |
| Dec 31, 2018 | 2.87 Mn |
| Sep 30, 2018 | 711,000.00 |
| Jun 30, 2018 | 1.02 Mn |
| Mar 31, 2018 | 3.43 Mn |
| Dec 31, 2017 | 23.34 Mn |